The Role of SliTrk5 in Central Nervous System

• Published in: BioMed research international Vol. 2022; pp. 1 - 10
• Main Authors: Liu, Yan, Zhang, Linming, Mei, Rong, Ai, Mingda, Pang, Ruijing, Xia, Di, Chen, Ling, Zhong, Lianmei
• Format: Journal Article
• Language: English
• Published: New York Hindawi 14.07.2022; John Wiley & Sons, Inc; Hindawi Limited
• Subjects: Amino acids; Attention deficit hyperactivity disorder; Autism; Axonogenesis; Binding sites; Brain cancer; Brain-derived neurotrophic factor; Cell adhesion & migration; Cellular signal transduction; Central nervous system; Central nervous system diseases; Chromosomes; Development and progression; Genetic aspects; Glioma; Health aspects; Kinases; Leucine; Membrane proteins; Mental illness; Morphogenesis; Movement disorders; Nervous system; Neurodegenerative diseases; Neurological disorders; Neurological research; Neurons; Obsessive compulsive disorder; Parkinson's disease; Pathogenesis; Proteins; Recovery of function; Review; Signal transduction; Stem cells; Synaptogenesis; Systems development; Tyrosine; China
• ISSN: 2314-6133; 2314-6141
• DOI: 10.1155/2022/4678026

SLIT and NTRK-like protein-5 (SliTrk5) is one of the six members of SliTrk protein family, which is widely expressed in the central nervous system (CNS), regulating and participating in many essential steps of central nervous system development, including axon and dendritic growth, neuron differentiation, and synaptogenesis. SliTrk5, as a neuron transmembrane protein, contains two important conservative domains consisting of leucine repeats (LRRs) located at the amino terminal in the extracellular region and tyrosine residues (Tyr) located at the carboxyl terminal in the intracellular domains. These special structures make SliTrk5 play an important role in the pathological process of the CNS. A large number of studies have shown that SliTrk5 may be involved in the pathogenesis of CNS diseases, such as obsessive-compulsive-disorder (OCD), attention deficit/hyperactivity disorder (ADHD), glioma, autism spectrum disorders (ASDs), and Parkinson’s disease (PD). Targeting SliTrk5 is expected to become a new target for the treatment of CNS diseases, promoting the functional recovery of CNS. The purpose of this article is to review the current research progression of the role of SliTrk5 in CNS and its potential mechanisms in CNS diseases.